Claim OwnershipNew Retina Radio by Eyetube
Subscribed: 120Played: 3,667
Subscribe
© 2024 Bryn Mawr Communications LLC
Description
New Retina Radio is a place to hear stories about retina that are told nowhere else.
212 Episodes
Reverse
How should retina specialists reframe their approach to GA therapy? In the final episode of this New Retina Radio miniseries, moderator John Kitchens, MD joins experts Margaret Chang, MD, MS; David Eichenbaum, MD; and Ferhina Ali, MD, MPH, to explore how to shift doctor mindsets from restoring vision to preserving it. The panel discusses challenges of counseling without clear imaging endpoints, the role of AI and microperimetry in demonstrating treatment value, and why some providers remain hesitant to adopt complement inhibitors. They also consider lessons from past therapies, tissue preservation as a meaningful endpoint, and how innovation may soon deliver more potent options.This content is editorially independent, supported by Astellas Pharma.
Should GA therapy start monthly—or is less-than-monthly treatment enough? In episode 3 of this New Retina Radio miniseries, moderator John Kitchens, MD joins David Eichenbaum, MD; Margaret Chang, MD, MS; and Ferhina Ali, MD, MPH, to share best practices in real-world GA care. The panel debates dosing strategy in light of long-term data, compares safety/efficacy considerations for pegcetacoplan vs avacincaptad pegol (including first-injection inflammation risk), and offers tips for initiating therapy in monocular patients. They also unpack evidence around AREDS vitamins and early experiences with photobiomodulation.This content is editorially independent, supported by Astellas Pharma.
How do you educate and empower patients to make informed decisions about geographic atrophy (GA) therapy? In episode 2 of this New Retina Radio miniseries, moderator John Kitchens, MD guides Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD, through practical strategies for patient education. The panel covers plain-language analogies for GA, using OCT and fundus photos, coordinating with optometry, and setting realistic expectations for FDA-approved treatments. They also tackle real-world barriers—visit burden, transportation, and costs—sharing tips on benefits investigations, manufacturer portals, and charity-care pathways.This content is editorially independent, supported by Astellas Pharma.
What does it mean to truly keep patients at the center of geographic atrophy (GA) therapy? In this first episode of a four-part New Retina Radio miniseries, moderator John Kitchens, MD, leads a discussion with experts Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD. The panel explores the social impact of GA and highlight the importance of early intervention, imaging, and patient education. Gain key insights into how clinicians can support patients navigating GA’s challenges.This content is editorially independent, supported by Astellas Pharma.
1What happens when patients with neovascular age-related macular degeneration (nAMD) show suboptimal response to faricimab (Vabysmo, Genentech/Roche) and are switched to high-dose aflibercept (Eylea HD, Regeneron)? Ben Young, MD, moderates a discussion with Pheobe Mellen, MD, and Jordan Deaner, MD, exploring real-world outcomes from a retrospective study of 135 eyes. The group dives into the implications for clinical practice and tries to parse apparently conflicting data regarding anatomic changes. Drs. Mellen and Deaner reflect on their own approaches to treating recalcitrant cases and debate what this paper means for the future of anti-VEGF therapy.
What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed? And Ehsan Rahimy, MD, reviews findings from a retrospective analysis seeking to understand if continuous glucose monitoring could reduce the risk of NPDR progressing to more serious conditions. Listen in to learn what he and his colleagues found.
Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision hold up at 5 years? And how do those numbers compare to 5-year endpoints in injection-based studies? John Kitchens, MD, reviews the dynamics around the PORTAL study, which assessed outcomes after 5 years of PDS treatment. And Krishna Mukkamala, MD, reviews data from a first-ever study validating longitudinal performance of AI-based home OCT (Scanly Home OCT, Notal Vision) compared with human experts. Just how sensitive and specific was home OCT compared with human graders?
What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to discuss a new retrospective cohort study by Rahimy et al. The panel explores how obstructive sleep apnea impacts the progression of diabetic retinopathy and elevates the risk for systemic vascular events such as stroke, heart attack, and death. With nearly 24,000 patients analyzed, the study sheds light on the importance of screening and managing comorbidities in patients with nonproliferative diabetic retinopathy—and raises critical questions about what role retina specialists should play in addressing them.
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.
The State of Geographic Atrophy Around the Globe: Part 1 of 2 DES: For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic route for treating geographic atrophy? And which pipeline therapeutic approaches could be useful to patients in the future? Anat Loewenstein, MD is joined by a world-class trio of retina specialists—Daniel Ting, MD, PhD; Paulo Eduardo Stanga, MD; and Patricio G. Schlottmann, MD—for a discussion exploring the state of play in GA from a global perspective. This podcast is part 1 of 2.
Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussion with Phoebe Mellen, MD, and Jordan Deaner, MD, about a new retrospective cohort study from the Duke Eye Center than examines differences in DR severity at presentation between patients from the lowest- and highest-income ZIP codes, explores how income-based barriers to care may impact disease progression, and discusses how this data might affect clinical care, screening strategies, and public health priorities.
What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions.
How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion.
What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists Hong-Uyen Hua, MD, and Louis Cai, MD, to examine a recent opinion piece published in JAMA Ophthalmology exploring what researchers can (and cannot) confidently conclude based on the study’s data.
Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manage proliferative vitreoretinopathy, Majda Hadziahmetovic, MD, shares new data on the effect of GLP-1 receptor agonists on diabetic retinopathy, Aleksandra V. Rachitskaya, MD, explains the value of multimodal Imaging in adults with a history of prematurity, and Gavin Tan, MD, PhD, FRCSed, discusses management approaches for myopic tractional maculopathy and macular holes.
Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pediatric retinal conditions that can manifest later in life, Jason Fan, MD, explains trends in anesthesia use for open-globe surgery, and Glenn J. Jaffe, MD, examines the role of AI in retina clinical trials.
During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, discussed her experiences delivering subretinal gene therapy, David Zacks, MD, PhD, explored important factors in retinal detachment repair, Xi Chen, MD, PhD, highlighted the various surgical approaches for young patients who present without a posterior vitreous detachment, and Yannek I. Leiderman, MD, PhD, provided pearls for scleral fixation of secondary IOLs.
Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodulation therapy realized any benefit after re-administration following a 13-month washout period. Did the break in treatment lead to irreversible vision loss? Or were patients able experience a benefit after taking more than a year off? We have the answers in this episode.
Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter? Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out.
How do GLP-1 drugs influence age-related ocular diseases such as macular degeneration and glaucoma? Moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to examine a retrospective study published in Ophthalmology using TriNetX data to compare 5-year ocular outcomes across medication cohorts. Do these data suggest a protective benefit for GLP-1s—and does it matter for clinical practice? Tune in for their take on what’s promising, what’s premature, and what’s next.
Comments
Download from Google Play
Download from App Store
United States